Biblio
Eculizumab Bridging Before Bone Marrow Transplant for Marrow Failure Disorders is Safe and Does Not Limit Engraftment. Biol Blood Marrow Transplant. 2018.
. Engineering the best transplant outcome for high-risk acute myeloid leukemia: the donor, the graft and beyond. Cytotherapy. 2023.
Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia. Blood Adv. 2018;2(16):2063-2071.
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv. 2020;4(8):1770-1779.
I Walk the Line: How to Tell MDS From Other Bone Marrow Failure Conditions. Curr Hematol Malig Rep. 2014.
. The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances. Cancer J. 2023;29(3):152-159.
. Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation. J Hematol Oncol. 2023;16(1):21.
Safety and efficacy of pembrolizumab prior to allogeneic stem cell transplant in Acute Myeloid Leukemia. Transplant Cell Ther. 2021.
Severe cytokine release syndrome after haploidentical peripheral blood transplantation. Biol Blood Marrow Transplant. 2019.
Stem cell donors should be screened for CHIP. Blood Adv. 2020;4(4):784-788.
.